-+ 0.00%
-+ 0.00%
-+ 0.00%

Natera Announces Launch Of TEODOR, A Randomized Trial Using ctDNA And Endocrine Responsiveness To Optimize Neoadjuvant Therapy

Benzinga·07/29/2025 11:11:40
Listen to the news

Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy